Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO Precis Oncol. 2022 09; 6:e2200072.

View in: PubMed

subject areas

B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung
CTLA-4 Antigen
Humans
Lung
Lung Neoplasms
Prospective Studies
Retrospective Studies
Small Cell Lung Carcinoma
Transcriptome

authors with profiles

Richard Schilsky